Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma

PURPOSE: Preclinical data suggest that anti-VEGF agents plus mTOR inhibitors yield synergistic antitumor effects. A phase I trial using a 3+3 dose escalation design of sunitinib (S) plus temsirolimus (T) was stopped after the first dose pair led to 2 of 3 patients experiencing dose-limiting toxicity...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Clin Genitourin Cancer
Main Authors: Campbell, Matthew T., Millikan, Randall E., Altinmakas, Emre, Xiao, Lianchun, Wen, Sin Jen, Siefker-Radtke, Arlene O., Aparicio, Ana, Corn, Paul G., Tannir, Nizar M.
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2014
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991027/
https://ncbi.nlm.nih.gov/pubmed/25465491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.10.004
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla